Top 500 Medicines Pharma
Transcript of Top 500 Medicines Pharma
-
8/9/2019 Top 500 Medicines Pharma
1/69
PharmaLive and Med Ad Newseditors have ranked thebest-selling prescription medicines by 2007 worldwidesales in this annual special report.
As part of this detailed report, the editors researchedand compiled the 2007, 2006, and 2005 worldwidesales information of the prescription medicines thatpharmaceutical, biotechnology, and specialty companies
manufacture and sell.
SPECIAL REPORT JULY 2008
TOP 500
PRESCRIPTION
MEDICINES
WHATYOUWILLFINDINTHISSPECIALREPORT
-
8/9/2019 Top 500 Medicines Pharma
2/69
2
What you will find in this special report(continued)
The information in this report is supplied by the companies. This document provides information on 500product sales entries representing about 100 companies. Some products that generate enough salesto make the top 500 list are not represented in these charts due to the unavailability of published salesdata. For instance, certain companies publish sales information for only billion-dollar brands, or for onlytheir top 10 or 20 drugs, etc. Certain companies do not publish any product sales data.
The data are sorted and presented in three formats: by the highest product 2007 global sales, by thecompanies that report sales for these products, and by the primary disease/medical use that eachproduct treats.
Some medicines are represented more than once in the Company chart because their sales are reportedseparately by more than one company due to joint promotion, joint marketing, or other types of alliancesand deals. In the Sales and Primary Disease/Medical Use charts, the products with more than onecompany are represented as one combined sales entry.
The charts provide the following information: 2007 sales rank for each medicine 2007, 2006 and 2005 worldwide sales for each medicine Companies that report sales for each medicine At least one primary disease/medical use that each medicine treats First approval date (or launch date if the original approval date is not applicable) of each medicine,and in some instances the region of occurrence is provided.
The top 500 prescription medicine entries of 2007 generated total sales of about $397 billion, comparedwith $369 billion for the same 500 drug entries during 2006 and $333 billion for 2005. The top-sellingprescription medicine remains Lipitor (lipitor.com). Launched during the first quarter of 1997, the HMG-CoA reductase inhibitor garnered 2007 sales of $12.68 billion for marketer Pfizer Inc. (pfizer.com). TokyosAstellas Pharma Inc. (astellas.com) reported Lipitor sales of 97.7 billion ($977 million) for the fiscalyear ended March 31, 2008. These combined sales of $13.65 billion compare with $13.83 billion for the
previous annual term. The No. 2 best-selling medicine worldwide in annual sales last year was Plavix/Iscover. Sales reached $8.08 billion in 2007, compared to $6.31 billion for 2006 when the product rankedthird overall. An antiplatelet agent indicated for a variety of atherothrombotic conditions, Plavix (plavix.com) was launched in 1998 in the United States. The medicine is marketed in more than 80 countries, insome regions under the trade name Iscover. Bristol-Myers Squibb Co. (bms.com) recorded Plavix salesof $4.76 billion for 2007. Sanofi-Aventis (sanofi-aventis.com) reported Plavix/Iscover sales of E2.42billion($3.32 billion) for last year.
Coming in at the No. 3 medicine sales rank was Advair/Seretide, at $6.99 billion for 2007.GlaxoSmithKline (gsk.com) reported Advair/Seretide sales of $6.63 billion in 2006 when the drug was theworlds No. 2 prescription seller. For treating asthma and chronic obstructive pulmonary disease, Advair(advair.com) was approved in the United States in 2000 and Seretide was cleared for EU marketing in1998. Climbing from the No. 11 sales rank (for 2005) to No. 7 (in 2006) to No. 4 last year was Enbrel.The tumor necrosis factor inhibitor generated $5.46 billion in 2007, up from $4.49 billion during theprevious term. Initially cleared for marketing in 1998, Enbrel (enbrel.com) is approved for a variety ofarthritic conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. For 2007,Enbrel sales were reported at $3.23 billion for Amgen (amgen.com) and $2.05 billion for Wyeth (wyeth.com). For the fiscal year ended March 31, 2008, Takeda (takeda.com) reported Enbrel sales of 18.8billion ($188 million). Ranking No. 14 in 2005 and No. 8 in 2006, Remicade was the No. 5 global sellerlast year at about $5.26 billion compared with $4.46 billion in the previous annum. Last years Remicadesales were reported to be $3.33 billion for Johnson & Johnson (jnj.com), $1.65 billion for Schering-Plough Corp. (sgp.com), and 28.6 billion ($286 million) for Mitsubishi Tanabe Pharma Corp. (mt-pharmaco.jp). Initially FDA approved in 1998, Remicade is a treatment for inflammatory diseases.
-
8/9/2019 Top 500 Medicines Pharma
3/69
3
TABLE OF CONTENTS
TOP 500 PRESCRIPTION MEDICINES BY SALESpages 5-27
TOP 500 PRESCRIPTION MEDICINES BY COMPANYpages 29-47
TOP 500 PRESCRIPTION MEDICINES BY PRIMARYDISEASE/MEDICAL USEpages 49-69
-
8/9/2019 Top 500 Medicines Pharma
4/69
TOP 500PRESCRIPTION
MEDICINES
BY SALES
-
8/9/2019 Top 500 Medicines Pharma
5/69
5
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
1 Lipitor 13,652
Pfizer 12,675
Astellas 977
13,833
Pfizer 12,886
Astellas 947
13,102
Pfizer 12,187
Astellas 915
Pfizer andAstellas Pharma
Cholesterol Dec. 17, 1996
2 Plavix/Iscover 8,079
BMS 4,755
Sanofi-Aventis3,324
6,313
BMS 3,257
Sanofi-Aventis3,056
6,601
BMS 3,823
Sanofi-Aventis2,778
Bristol-Myers Squibband Sanofi-Aventis
Atherothrombosis Nov. 17, 1997/1998
3 Advair/Seretide 6,998 6,626 6,006 GlaxoSmithKline Asthma Aug. 24, 2000/Sept. 7, 1998
4 Enbrel 5,463
Amgen 3,230
Wyeth 2,045
Takeda 188
4,493
Amgen 2,879
Wyeth 1,500
Takeda 114
3,707
Amgen 2,573
Wyeth 1,084
Takeda 50
Amgen,Wyeth,TakedaPharmaceutical
Rheumatoid arthritis Nov. 2, 1998
5 Remicade 5,261
J&J 3,327
Schering-Plough
1,648
MitsubishiTanabe 286
4,458
J&J 3,013
Schering-Plough
1,240
Mitsubishi 205
3,605
J&J 2,535
Schering-Plough
942
Mitsubishi 128
Johnson & Johnson,Schering-Plough,Mitsubishi TanabePharma
Rheumatoid arthritis Aug. 24, 1998
6 Nexium 5,216 5,182 4,633 AstraZeneca Gastrointestinal disorders March 2000 (Sweden)
7 Rituxan/MabThera
Notes: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent companyRoche
Biogen Idec recordsU.S. joint-promotionprofitt
5,214
Roche 4,597(includesGenentech2,285 andChugai 159)
Biogen Idec 617
Zenyaku KogyoNA
4,589
Roche 4,033(includesGenentech2,071 andChugai 154)
Biogen Idec 556
Zenyaku KogyoNA
3,976
Roche 3,462(includesGenentech1,832 andChugai 152)
Biogen Idec 514
Zenyaku KogyoNA
Roche,Genentech,Biogen Idec,ChugaiPharmaceutical,Zenyaku Kogyo
Non-Hodgkins lymphoma Nov. 26, 1997/June 2, 1998
8 Diovan and DiovanHCT/CoDiovan
5,012 4,223 3,676 Novartis Hypertension Dec. 23, 1996 andMarch 6, 1998/Oct. 6, 1997
9 Zyprexa 4,761 4,364 4,202 Eli Lilly Schizophrenia Sept. 27, 1996
10 Risperdal, RisperdalConsta, Invega
4,697 4,183 3,552 Johnson & Johnson Schizophrenia Dec. 29, 1993,Oct. 29, 2003,Dec. 19, 2006
11 Actos 4,333
Takeda 3,962
Eli Lilly 371
3,812
Takeda 3,363
Eli Lilly 449
2,931
Takeda 2,438
Eli Lilly 493
TakedaPharmaceutical andEli Lilly
Type 2 diabetes July 15, 1999
12 Singulair 4,266 3,579 2,976 Merck & Co. Asthma Feb. 20, 1998
13 Protonix/Pantozol/Pantoloc
(pantoprazole)
Notes: Nycomedacquired AltanaPharma andPantoprazoleDec. 29, 2006.
Solvay lost Pantolocmarketing rightsin Canada during2006.
4,221
Nycomed 2,310(Pantoprazole,includingPantozol)
Wyeth 1,911(Protonix)
Solvay 0(Pantoloc)
4,017
Altana 2,126(Pantoprazole,includingPantozol)
Wyeth 1,795(Protonix)
Solvay 96(Pantoloc)
3,779
Altana 1,866(Pantoprazole,includingPantozol)
Wyeth 1,685(Protonix)
Solvay 228(Pantoloc)
Nycomed andWyeth
Gastrointestinal disorders Feb. 2, 2000/1994/1997
14 Seroquel 4,219
AstraZeneca4,027
Astellas 192
3,584
AstraZeneca3,416
Astellas 168
2,913
AstraZeneca2,761
Astellas 152
AstraZeneca andAstellas Pharma
Schizophrenia Sept. 26, 1997
-
8/9/2019 Top 500 Medicines Pharma
6/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
6
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
15 Herceptin
Note: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent company
Roche
4,044
Roche 4,044(includesGenentech1,287 andChugai 138)
3,273
Roche 3,273(includesGenentech1,234 andChugai 124)
1,788
Roche 1,788(includesGenentech 747and Chugai 96)
Roche,Genentech,ChugaiPharmaceutical
Breast cancer Sept. 25, 1998
16 Prevacid/Takepron(lansoprazole)
3,962
Tap 2,275(Prevacid)
Takeda 1,487(Lansoprazole,including 648 forTakepron)
Abbott 200(Lansoprazole)
4,280
Tap 2,600(Prevacid)
Takeda 1,507(Lansoprazole,including 579 forTakepron)
Abbott 173(Lansoprazole)
4,254
Tap 2,501(Prevacid)
Takeda 1,599(Lansoprazole,including 550 forTakepron)
Abbott 154(Lansoprazole)
Tap PharmaceuticalProducts,TakedaPharmaceutical,Abbott Laboratories
Gastrointestinal disorders May 10,1995/1991
17 Effexor line 3,794 3,722 3,459 Wyeth Depression Dec. 28, 1993
18 Aranesp 3,614 4,121 3,273 Amgen Anemia June 11, 2001
19 Lovenox/Clexane 3,581 3,339 2,938 Sanofi-Aventis Deep-vein thrombosis March 29, 1993/September 1997
20 Atacand/Blopress(candesartan)
3,518
Takeda 2,231(Blopress/candesartan)
AstraZeneca1,287 (Atacand)
3,172
Takeda 2,062(Blopress/candesartan)
AstraZeneca1,110 (Atacand)
2,883
Takeda 1,909(Blopress/candesartan)
AstraZeneca 974(Atacand)
TakedaPharmaceutical andAstraZeneca
Hypertension June 4, 1998/Oct. 6, 1997
21 Avastin
Note: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent companyRoche.
3,422
Roche 3,422(includesGenentech2,296 andChugai 30)
2,469
Roche 2,469(includesGenentech1,746; Chugai0 = June 2007Japan launch
1,388
Roche 1,388(includesGenentech1,133)
Roche,Genentech,ChugaiPharmaceutical
Colorectal cancer Feb. 26, 2004(U.S. approval)
22 Cozaar and Hyzaar 3,350 3,163 3,037 Merck & Co. Hypertension April 14, 1995, andApril 28, 1995
23 Copaxone 3,327
Teva 1,713
Sanofi-Aventis1,614
2,880
Teva 1,414
Sanofi-Aventis1,466
2,413
Teva 1,176
Sanofi-Aventis1,237
Teva PharmaceuticalIndustries andSanofi-Aventis
Multiple sclerosis Dec. 20, 1996
24 Aricept 3,311
Eisai 2,910
Pfizer 401
2,887
Eisai 2,529
Pfizer 358
2,311
Eisai 1,965
Pfizer 346
Eisai and Pfizer Alzheimers disease Nov. 25, 1996
25 AcipHex/Pariet 3,116
Eisai 1,759
J&J 1,357
2,982
Eisai 1,743
J&J 1,239
2,714
Eisai 1,545
J&J 1,169
Eisai andJohnson & Johnson
Gastrointestinal disorders Aug. 19, 1999/1997
26 Humira 3,064 2,044 1,400 Abbott Laboratories Rheumatoid arthritis Dec. 31, 2002
27 Gleevec/Glivec 3,050 2,554 2,170 Novartis Leukemia May 10, 2001/June 26, 2001
28 Fosamax 3,049 3,134 3,191 Merck & Co. Osteoporosis Sept. 29, 1995
29 Lexapro/Cipralex 3,044
Forest 2,292(Lexapro)
Lundbeck 752(Cipralex)
2,751
Forest 2,106(Lexapro)
Lundbeck 645(Cipralex)
2,355
Forest 1,873(Lexapro)
Lundbeck 482(Cipralex)
Forest LaboratoriesandH. Lundbeck
Major depressive disorder Aug. 14, 2002/2002
30 Norvasc 3,001 4,866 4,706 Pfizer Hypertension July 31, 1992
31 Neulasta 3,000 2,710 2,288 Amgen Neutropenia Jan. 31, 2002
-
8/9/2019 Top 500 Medicines Pharma
7/69
7
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
32 Crestor 2,900
AstraZeneca2,796
Shionogi 104
2,053
AstraZeneca2,028
Shionogi 25
1,269
AstraZeneca1,268
Shionogi 1
AstraZeneca andShionogi
Cholesterol Nov. 7, 2002
33 Procrit/Eprex 2,885 3,180 3,324 Johnson & Johnson Anemia Dec. 31, 1990/
May 4, 199534 Levaquin/Cravit
(levofloxacin) andFloxin, Floxin Otic
2,862J&J 1,646
(Levaquin,Floxin, FloxinOtic)
Daiichi Sankyo1,087 (Cravit/levofloxacin)
Santen 129(Cravit)
2,703
J&J 1,530(Levaquin,Floxin, FloxinOtic)
Daiichi Sankyo1,041 (Cravit/levofloxacin)
Santen 132(Cravit)
2,639
J&J 1,492(Levaquin,Floxin, FloxinOtic)
Daiichi Sankyo1,015 (Cravit/levofloxacin)
Santen 132(Cravit)
Johnson & Johnson,
Daiichi Sankyo,
SantenPharmaceutical
Bacter ial infections Levaquin: Dec. 20, 1996
Cravit: 1993
Floxin: Dec. 28, 1990
Floxin Otic: Dec. 16, 1997
35 Lantus 2,785 2,284 1,665 Sanofi-Aventis Type 2 diabetes andtype 1 diabetes
April 20, 2000
36 Vytorin 2,779 1,955 1,028 Merck/Schering-Plough
Pharmaceuticals
Cholesterol July 23, 2004
37 Avapro/Aprovel andAvalide/CoAprovel
2,685
Sanofi-Aventis1,481 (Aproveland CoAprovel)
Bristol-MyersSquibb 1,204(Avapro/Aproveland Avalide/CoAprovel)
2,489
Sanofi-Aventis1,392 (Aproveland CoAprovel)
Bristol-MyersSquibb 1,097(Avapro/Aproveland Avalide/CoAprovel)
2,205
Sanofi-Aventis1,223 (Aproveland CoAprovel)
Bristol-MyersSquibb 982(Avapro/Aproveland Avalide/CoAprovel)
Sanofi-AventisandBristol-Myers Squibb
Hypertension Avapro: Sept. 30, 1997
Aprovel: Aug. 27, 1997
Avalide: Sept. 30, 1997
CoAprovel:Oct. 15, 1998
38 Taxotere 2,569 2,402 2,206 Sanofi-Aventis Cancer Oct. 27, 1995
39 Abilify
Note: 2007-2005total figures are
estimates; 2007-2005 U.S. sales areactual numbers.
2,490(estimate)
Bristol-Myers
Squibb 1,660
Otsuka 830(estimate)
*2007 U.S. salesfor BMS andOtsuka total2,160.
1,923(estimate)
Bristol-Myers
Squibb 1,282
Otsuka 641(estimate)
*2006 U.S. salesfor BMS andOtsuka total1,623.
1,368(estimate)
Bristol-Myers
Squibb 912
Otsuka 456(estimate)
*2005 U.S. salesfor BMS andOtsuka total1,159.
Bristol-Myers SquibbandOtsukaPharmaceutical
Schizophrenia Nov. 15, 2002
40 Epogen 2,489 2,511 2,455 Amgen Anemia June 1, 1989
41 Spiriva 2,457 1,893 1,304 Boehringer Ingelheim Chronic obstructivepulmonary disease
April 2002
42 Topamax 2,453 2,027 1,680 Johnson & Johnson Seizures Dec. 24, 1996
43 Prevnar 2,439 1,961 1,508 Wyeth Pneumococcal disease Feb. 17, 2000
44 Zetia 2,407 1,929 1,397 Merck/Schering-Plough
Pharmaceuticals
Cholesterol Oct. 25, 2002
45 Celebrex/Celecox 2,327
Pfizer 2,290
Astellas 37(June 2007Japan launch)
2,039(Pfizer)
1,730(Pfizer)
Pfizer andAstellas Pharma
Osteoarthritis andrheumatoid arthritis
Celebrex: February1999 (U.S. launch)
Celecox: June 11, 2007(Japan launch)
-
8/9/2019 Top 500 Medicines Pharma
8/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
8
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
46 Zyrtec/Cirrus andZyrtec-D
Note:GlaxoSmithKlinejointly marketsZyrtec in Japan.
2,317+
Pfizer 1,541(Zyrtec andZyrtec-D)
UCB 668(Zyrtec/Cirrus
and Zyrtec-D)
Daiichi Sankyo108 (Zyrtec)
GlaxoSmithKlineNA(Zyrtec)
2,458+
Pfizer 1,569(Zyrtec andZyrtec-D)
UCB 769(Zyrtec/Cirrus
and Zyrtec-D)
Daiichi Sankyo120 (Zyrtec)
GlaxoSmithKlineNA(Zyrtec)
2,259+
Pfizer 1,362(Zyrtec andZyrtec-D)
UCB 771(Zyrtec/Cirrus
and Zyrtec-D)
Daiichi Sankyo126 (Zyrtec)
GlaxoSmithKlineNA(Zyrtec)
Pfizer,UCB,Daiichi Sankyo
Allergic rhinitis Dec. 8, 1995/NA andAug. 10, 2001
47 Lamictal 2,194 1,992 1,698 GlaxoSmithKline Seizures Dec. 27, 1994
48 Micardis 2,166
Boehringer 1,540
Astellas 626
1,829
Boehringer 1,326
Astellas 503
1,366Boehringer 993
Astellas 373
Boehringer IngelheimandAstellas Pharma
Hypertension Nov. 10, 1998
49 Benicar/Olmetecand Benicar HCT(olmesartan)
Note: Forestrecords U.S. jointpromotion profit.
2,104
Daiichi 1,892
(Benicar/Olmetec andBenicar HCT(olmesartan))
Forest 212(Benicar andBenicar HCT)
1,622
Daiichi 1,447
(Benicar/Olmetec andBenicar HCT(olmesartan))
Forest 175(Benicar andBenicar HCT)
1,038
Daiichi 924
(Benicar/Olmetec andBenicar HCT(olmesartan))
Forest 114(Benicar andBenicar HCT)
Daiichi SankyoandForest Laboratories
Hypertension April 25, 2002/2002 andJune 5, 2003
50 Cymbalta 2,103 1,316 680 Eli Lilly Depressive disorder Aug. 3, 2004
51 Eloxatin/Eloxatine 2,085 2,321 2,144 Sanofi-Aventis Colorectal cancer Aug. 9, 2002/September 1996
52 Prograf 2,030 1,754 1,459 Astellas Pharma Transplant rejection April 2, 1993
53 Lupron/Leuplin(leuprolide)
1,885Takeda 1,240(Leuprorelin,including 664 for
Leuplin)
Tap 645 (Lupron)
Abbott NA(Leuprolide)
2,167
Takeda 1,275(Leuprorelin,including 643 for
Leuplin)
Tap 662 (Lupron)
Abbott 230(Leuprolide)
2,142
Takeda 1,224(Leuprorelin,including 632 for
Leuplin)
Tap 699 (Lupron)
Abbott 219(Leuprolide)
TakedaPharmaceutical andTap PharmaceuticalProducts
Prostate cancer Jan. 26, 1989/July 5, 2002
54 Avonex 1,868 1,707 1,543 Biogen Idec Multiple sclerosis May 17, 1996
54 Valtrex 1,868 1,690 1,390 GlaxoSmithKline Herpes June 23, 1995
56 Lyrica 1,829 1,156 291 Pfizer Neuropathic pain July 6, 2004
57 TriCor/Lipanthyl 1,812
Abbott 1,218(TriCor)
Solvay 594(TriCor/Lipanthyl)
1,614Abbott 1,048(TriCor)
Solvay 566(TriCor/Lipanthyl)
1,181
Abbott 927(TriCor)
Solvay 254(TriCor/Lipanthyl)
Abbott Laboratoriesand Solvay
Cholesterol Feb. 9, 1998/June 1999
58 Viagra 1,764 1,657 1,645 Pfizer Erect ile dysfunction March 27, 1998
59 Avandia 1,754 2,798 2,308 GlaxoSmithKline Type 2 diabetes May 25, 1999
60 Actonel
Notes: 2007 total isactual worldwidefigure; P&G figuresare estimates.
Eisai marketsActonel in Japan.
1,750(actual)
P&G 1,229(estimate)
Sanofi-Aventis439
Eisai 82
1,663(estimate)
P&G 1,106(estimate)
Sanofi-Aventis481
Eisai 75
1,582(estimate)
P&G 1,043(estimate)
Sanofi-Aventis499
Eisai 40
Procter & Gamble,Sanofi-Aventis,Eisai
Osteoporosis March 27, 1998
-
8/9/2019 Top 500 Medicines Pharma
9/69
9
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
61 NeoRecormon/Epogin
Note: Chugaireports Japansales that are alsorecorded by parentcompany Roche.
1,745Roche 1,745(includesChugai 468)
1,856Roche 1,856(includesChugai 542)
1,877Roche 1,877(includesChugai 614)
Roche andChugaiPharmaceutical
Anemia July 16, 1997/April 1990
62 Tamiflu
Note: Chugaireports Japansales that are alsorecorded by parentcompany Roche.
1,738
Roche 1,738(includesChugai 331)
2,189
Roche 2,189(includesChugai 325)
1,298
Roche 1,298(includesChugai 301)
Roche andChugaiPharmaceutical
Influenza Oct. 27, 1999
63 Arimidex 1,730 1,508 1,181 AstraZeneca Breast cancer Dec. 27, 1995
64 Ambien/Stilnox 1,714 2,778 2,083 Sanofi-Aventis Insomnia Dec. 16, 1992/June 9, 1987
65 CellCept 1,677
Roche 1,677
Chugai NA
1,535
Roche 1,535(includesChugai 30)
1,421
Roche 1,421
Chugai 0
Roche andChugaiPharmaceutical
Transplant rejection May 3, 1995(U.S. approval)
66 Rebif
Note: Serono wasacquired by MerckKGaA Jan. 5, 2007.
1,670 1,452
(Serono)
1,270
(Serono)
Merck KGaA Multiple sclerosis February 1998
67 Xalatan andXalacom
1,604 1,453 1,372 Pfizer Intraocular pressure June 5, 1996, andsecond-quarter 2001
68 Gemzar 1,592 1,408 1,335 Eli Lilly Cancer May 15, 1996
69 Truvada 1,589 1,194 568 Gilead Sciences HIV infection Aug. 2, 2004
70 Depakote 1,575 1,308 1,096 Abbott Laboratories Seizures March 10, 1983
70 Symbicort 1,575 1,184 1,006 AstraZeneca Asthma August 2000
72 Gardasil 1,481 235 0 Merck & Co. Cervical cancer June 8, 2006
73 Humalog 1,475 1,300 1,198 Eli Lilly Diabetes April 30, 1996
74 Pulmicort 1,454 1,292 1,162 AstraZeneca Asthma June 24, 1997
75 Toprol-XL/Seloken 1,438 1,795 1,735 AstraZeneca Hypertension Jan. 10, 1992/1996
76 Yasmin, Yaz,Yasminelle
Note: 2006 figure ispro forma for Bayerafter Schering AGproductsacquisition as ofJune 23, 2006.
1,429 1,089 803(Schering AG)
Bayer Prevention of pregnancy Yasmin: March 2000(Netherlands approval)
Yaz: March 2006(U.S. approval)
Yasminelle: August 2005(Netherlands approval)
77 Betaseron/Betaferon
Notes: Bayer 2006figure is pro formaafter Schering AGproducts acquisitionas of June 23, 2006.
Chiron was acquiredby Novartis in April2006.
1,409
Bayer 1,409
Novartis NA
1,402
Bayer 1,359
Chiron 43(estimate thruApril 2006)
1,214
Schering 1,072
Chiron 142
Bayer and Novartis Multiple sclerosis July 23, 1993/Nov. 30, 1995
78 Keppra 1,407 1,043 768 UCB Seizures Nov. 30, 1999
79 Flomax 1,399 1,264 989 Boehringer Ingelheim Benign prostatichypertrophy
Oct. 8, 1997
80 Imitrex/Imigran 1,370 1,422 1,394 GlaxoSmithKline Migraine Dec. 28, 1992/1990
81 Pegasys
Note: Chugaireports Japansales that are alsorecorded by parentcompany Roche.
1,364
Roche 1,364(includesChugai 54)
1,223
Roche 1,223(includesChugai 50)
1,169
Roche 1,169(includesChugai 68)
Roche andChugaiPharmaceutical
Hepatitis C June 21, 2002
-
8/9/2019 Top 500 Medicines Pharma
10/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
10
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
82 Erbitux 1,336
Bristol-MyersSquibb 692
Merck KGaA 644
1,114
Bristol-MyersSquibb 652
Merck KGaA 462
712
Bristol-MyersSquibb 413
Merck KGaA 299
Bristol-Myers Squibband Merck KGaA
Colorectal cancer Feb. 12, 2004
83 Casodex 1,335 1,206 1,123 AstraZeneca Prostate cancer Oct. 4, 1995
84 Kaletra 1,325 1,135 1,005 Abbott Laboratories HIV infection March 9, 2001
85 Zometa 1,297 1,283 1,224 Novartis Hypercalcemia Aug. 21, 2000
86 Neupogen 1,277 1,213 1,216 Amgen Neutropenia Feb. 20, 1991
87 Evista 1,265
Eli Lilly 1,091
Chugai 137
Daiichi 37
1,178
Eli Lilly 1,045
Chugai 115
Daiichi 18
1,115
Eli Lilly 1,036
Chugai 79
Daiichi 0
Eli L illy,ChugaiPharmaceutical,Daiichi Sankyo
Osteoporosis Dec. 9, 1997
88 Flovent/Flixotide 1,242 1,318 1,276 GlaxoSmithKline Asthma March 27, 1996/March 13, 1995
89 Atripla (efavirenz) 1,238
Gilead 903(Atripla)
Bristol-MyersSquibb 335(efavirenz)
281
Gilead 206(Atripla)
Bristol-MyersSquibb 75(efavirenz)
0 Gilead Sciences andBristol-Myers Squibb
HIV infection July 12, 2006
90 Harnal 1,224 1,270 1,378 Astellas Pharma Benign prostatichypertrophy
July 1992
91 Lucentis
Note: Genentechreports U.S. sales thatare also recordedby parent companyRoche
1,219
Roche 826(includesGenentech 815)
Novartis 393
417
Roche 398(includesGenentech 380)
Novartis 19
0 Roche,Genentech,Novartis
Wet age-related maculardegeneration
June 30, 2006
92 Botox 1,212 982 831 Allergan Cervical dystonia Dec. 29, 1989
93 Pravacholand Mevalotin(pravastatin)
1,192
BMS 443(Pravachol)
Daiichi 749(Mevalotin/pravastatin)
2,132
BMS 1,197(Pravachol)
Daiichi 935(Mevalotin/pravastatin)
3,688
BMS 2,256(Pravachol)
Daiichi 1,432(Mevalotin/pravastatin)
Bristol-Myers Squibband Daiichi Sankyo
Cholesterol Oct. 31, 1991, and 1988
94 Detrol and Detrol LA 1,190 1,100 988 Pfizer Overactive bladder March 25, 1998, andDec. 22, 2000
95 Coreg 1,174 1,558 1,146 GlaxoSmithKline Hypertension Sept. 14, 1995
96 Duragesic/FentanylTransdermal
1,164 1,295 1,585 Johnson & Johnson Pain Duragesic: Aug. 7, 1990
97 Synagis
Notes: MedImmunewas acquired byAstraZeneca inJune 2007.
Abbott completedthe U.S. jointpromotion ofSynagis inDecember 2006;Abbott recordedU.S. joint-promotionrevenue.
1,161(estimate)AstraZeneca 618
MedImmune
543 (First-half2007 estimate)
Abbott 0
DainipponSumitomo 0
1,438
AstraZeneca 0
MedImmune1,065
Abbott 373
DainipponSumitomo 0
1,414
AstraZeneca 0
MedImmune1,063
Abbott 231
DainipponSumitomo 120
AstraZeneca Respiratory syncytial virus June 19, 1998
-
8/9/2019 Top 500 Medicines Pharma
11/69
11
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
98 Cialis
Note: Eli Lillyacquired all ofthe outstandingcommon stockof Icos, thecompanys partner
in the Lilly Icosjoint venture for themanufacture andsales of Cialis, asof Jan. 29, 2007.
1,144Eli Lilly 1,144
Lilly Icos 0
971
Lilly Icos 755
Eli Lilly 216
747Lilly Icos 577
Eli Lilly 170
Eli Lilly Erect ile dysfunction Nov. 14, 2002
99 Prilosec/Losec 1,143 1,371 1,652 AstraZeneca Gastrointestinal disorders Sept. 14, 1989/1987
100 Zosyn/Tazocin 1,137 972 892 Wyeth Bacterial infections Oct. 22, 1993/Dec. 18, 1995
101 Cerezyme 1,130 1,007 932 Genzyme Gauchers disease April 5, 1991
102 Reyataz 1,124 931 696 Bristol-Myers Squibb HIV infection Jan. 6, 2003
103 Kogenate 1,121 1,079 909 (Bayer) Bayer Hemophilia Feb. 25, 1993
104 Wellbutrin XL 1,120
GlaxoSmithKline908
Biovail 212
2,046
GlaxoSmithKline1,596
Biovail 450
1,648
GlaxoSmithKline1,294
Biovail 354
GlaxoSmithKline andBiovail
Depression Aug. 28, 2003
105 Paxil/Seroxat 1,106 1,240 1,230 GlaxoSmithKline Depression Dec. 29, 1992/October 1998
106 Zoladex 1,104 1,008 1,004 AstraZeneca Prostate cancer Dec. 29, 1989
107 Nasonex 1,092 944 737 Schering-Plough Allergic rhinitis Oct. 1, 1997
108 Infanrix and Pediarix 1,086 1,022 862 GlaxoSmithKl ine Diphther ia, tetanus, andpertussis
January 1996 andDec. 13, 2002
109 NovoSeven 1,078 1,036 931 Novo Nordisk Bleeding due tohemophilia
Feb. 23, 1996
110 Boniva/Bonviva 1,061
Roche 739
GlaxoSmithKline
322
597
Roche 407
GlaxoSmithKline
190
108
Roche 72
GlaxoSmithKline
36
Roche andGlaxoSmithKline
Osteoporosis March 24, 2005/February 2004
111 Augmentin 1,060 1,140 1,332 GlaxoSmithKline Bacterial infections Aug. 6, 1984
112 GlaxoSmithKlinehepatitis vaccines(primarily Engerix-B,Havrix, Twinrix)
1,058 958 888 GlaxoSmithKline Hepatitis Aug. 28, 1989,Feb. 22, 1995,September 1996
113 Premarin, Prempro,Premphase
1,055 1,051 909 Wyeth Menopausal symptoms 1942, Nov. 17, 1995,Nov. 17, 1995
114 Tarceva
Note: Genentechreports U.S. salesand Chugai reportsJapan sales thatare also recordedby parent companyRoche.
1,054
Roche 885(includesGenentech 417and Chugai 3)
OSI 169
833
Roche 678(includesGenentech 402and Chugai 0)
OSI 155
408
Roche 323(includesGenentech 275and Chugai 0)
OSI 85
Roche,Genentech,ChugaiPharmaceutical,OSI Pharmaceuticals
Non-small cell lung cancer Nov. 18, 2004
115 Adderall XR 1,031 864 731 Shire PharmaceuticalsGroup
Attention-deficithyperactivity disorder
Oct. 11, 2001
116 Concerta 1,028 930 774 Johnson & Johnson Attention-deficithyperactivity disorder
Aug. 1, 2000
117 Sandostatin 1,027 915 896 Novartis Acromegaly Oct. 21, 1988
118 Delix and Tritace 1,016 1,340 1,383 Sanofi-Aventis Hypertension July 7, 2000, andJuly 6, 2000
119 Avelox/Avalox 1,013
Bayer 610
Schering-Plough384
Shionogi 19
871
Bayer 543
Schering-Plough304
Shionogi 24
745
Bayer 499
Schering-Plough228
Shionogi 18
Bayer,Schering-Plough,Shionogi
Bacterial infections Dec. 10, 1999/June 21, 1999
-
8/9/2019 Top 500 Medicines Pharma
12/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
12
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
120 Humulin 985 925 1,005 Eli Lilly Diabetes Oct. 28, 1982
121 Tracleer 983 749 528 Actelion Pulmonary arterialhypertension
Nov. 20, 2001
122 Camptosar 969 903 910 Pfizer Colorectal cancer June 14, 1996
123 Allegra/Telfast 968 943 1,844 Sanofi-Aventis Allergic rhinitis July 25, 1996/Dec. 3, 1996
124 Byetta 967Amylin 636
Eli Lilly 331
649Amylin 430
Eli Lilly 219
150Amylin 75
Eli Lilly 75
AmylinPharmaceuticalsandEli Lilly
Type 2 diabetes April 28, 2005
125 Xeloda
Note: Chugai reportsJapan sales thatare also recordedby parent companyRoche.
959Roche 959(includesChugai 23)
809Roche 809(includesChugai 21)
663Roche 663(includesChugai 23)
Roche andChugaiPharmaceutical
Cancer 1998
126 Femara
Note: Chugai reportsJapan sales thatare also recorded
by parent companyRoche.
945
Novartis 937
Roche 9
(via Chugai 9)
722
Novartis 719
Roche 3
(via Chugai 3)
536
Novartis
Roche/Chugai 0
Novartis,Roche,ChugaiPharmaceutical
Breast cancer July 25, 1997
127 Neoral andSandimmun
944 918 953 Novartis Transplant rejection July 14, 1995, andNov. 14, 1983
127 Zyvox 944 782 618 Pfizer Bacterial infections April 18, 2000
129 Ortho hormonalcontraceptives
925 1,016 1,136 Johnson & Johnson Contraception NA
130 PegIntron 911 837 751 Schering-Plough Hepatitis C May 25, 2000
131 Combivir 910 1,056 1,166 GlaxoSmithKline HIV infection Sept. 26, 1997
132 Combivent 887 920 769 Boehringer Ingelheim Chronic obstructivepulmonary disease
Oct. 24, 1996
133 Mirapex/Sifrol 883 735 595 Boehringer Ingelheim Parkinsons disease July 1, 1997/Oct. 14, 1997
133 Chantix/Champix 883 101 0 Pfizer Smoking cessation May 10, 2006/Sept. 29, 2006
135 Zocor 877 2,803 4,382 Merck & Co. Cholesterol Dec. 23, 1991
136 Temodar 861 703 588 Schering-Plough Brain tumors Aug. 11, 1999
137 Varivax 855 328 NA Merck & Co. Chickenpox March 17, 1995
138 Geodon/Zeldox 854 758 589 Pfizer Schizophrenia Feb. 5, 2001/May 2002
138 Alimta 854 612 463 Eli Lilly Non-small cell lung cancer Feb. 4, 2004
140 Provigil 852 735 513 Cephalon Sleepiness Dec. 24, 1998
141 Genotropin 843 795 808 Pfizer Growth failure Aug. 24, 1995
142 Adalat 842 901 904 Bayer Hypertension Nov. 27, 1985
143 Namenda 830 660 508 Forest Laboratories Alzheimers disease Oct. 16, 2003
144 Clarinex/Aerius 799 722 646 Schering-Plough Allergic rhinitis Dec. 21, 2001/Jan. 15, 2001
145 Trusopt and Cosopt 787 697 617 Merck & Co. Intraocular pressure Dec. 9, 1994, andApril 7, 1998
146 Revlimid 774 321 3 Celgene Multiple myeloma,myelodysplastic syndrome
Dec. 27, 2005
147 Merrem 773 604 505 AstraZeneca Bacterial infections June 21, 1996
148 Primaxin 764 705 740 Merck & Co. Bacterial infections Nov. 26, 1985
149 Ultane/Sevorane 759 799 874 Abbott Laboratories Anesthesia June 7, 1995/1994
150 Lotrel 748 1,352 1,075 Novartis Hypertension June 16, 1999
151 Voltaren group 747 690 689 Novartis Pain July 28, 1998
152 Biaxin 724 816 1,065 Abbott Laboratories Bacterial infections Oct. 31, 1991
153 Forteo 709 594 389 Eli Lilly Osteoporosis Nov. 26, 2002
-
8/9/2019 Top 500 Medicines Pharma
13/69
13
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
154 Lidoderm 706 567 419 EndoPharmaceuticalsHoldings
Pain March 19, 1999
155 Vesicare 701Astellas 601
GlaxoSmithKline100
426Astellas 362
GlaxoSmithKline64
174Astellas 148
GlaxoSmithKline26
Astellas Pharma andGlaxoSmithKline
Overactive bladder July 9, 2004
156 Comtan/Comtressand Stalevo
695
Novartis 420(Comtan/Stalevo group)
Orion 275(Stalevo 174 andComtan/Comtess 101)
585
Novartis 330(Comtan/Stalevo group)
Orion 255(Stalevo 153 andComtan/Comtess 102)
477
Novartis 278(Comtan/Stalevo group)
Orion 199(Stalevo 102 andComtan/Comtess 97)
Novartis and Orion Parkinsons disease Oct. 19, 1999/Sept. 16, 1998 andJune 11, 2003
157 Trileptal 692 721 615 Novartis Seizures November 1999
157 Requip 692 536 312 GlaxoSmithKline Parkinsons disease Sept. 19, 1997
159 Januvia 668 43 0 Merck & Co. Type 2 diabetes Oct. 16, 2006
160 Lescol group 665 725 767 Novartis Cholesterol Dec. 31, 1993
161 Niaspan
Notes: Abbottacquired KosPharmaceuticalsalong with Niaspanin December 2006.
Kos 2006 figure isa full-year estimatebased on Niaspannine-month 2006sales.
658(Abbott)
498(estimate)
435(Kos)
Abbott Laboratories Cholesterol July 28, 1997
162 Renagel
Note: Chugaireports Japansales that are alsorecorded by parentcompany Roche.
652
Genzyme 603
Roche 49(via Chugai 49)
559
Genzyme 515
Roche 44(via Chugai 44)
457
Genzyme 418
Roche 39(via Chugai 39)
Genzyme,Roche,ChugaiPharmaceutical
Hyperphosphatemia Oct. 30, 1998
163 Epzicom/Kivexa 648 482 236 GlaxoSmithKline HIV infection Aug. 2, 2004/December 2004
164 Altace 646 653 554 King Pharmaceuticals Cardiovascular events Jan. 28, 1991
165 Norditropin 645 608 511 Novo Nordisk Growth hormonedeficiency
1997
166 GlaxoSmithKlineinfluenza vaccines(primarily Fluarixand FluLaval/Fluviral)
640 340 NA GlaxoSmithKline Influenza Aug. 31, 2005, andOct. 5, 2006/Sept. 10, 2004
167 Amlodin 636 592 568 Dainippon Sumitomo Hypertension, anginapectoris
NA
168 Exelon 632 525 467 Novartis Alzheimers disease May 12, 1998
168 Vfend 632 515 397 Pfizer Fungal infections March 21, 2002170 Sustiva 621 715 680 Bristol-Myers Squibb HIV infection Sept. 17, 1998
171 Viread 613 689 779 Gilead Sciences HIV infection Oct. 26, 2001
171 Xolair
Note: Genentechreports U.S. salesthat are alsorecorded by parentcompany Roche.
613
Roche 473(includesGenentech 472)
Novartis 140
550
Roche 448(includesGenentech 425)
Novartis 102
345
Roche 340(includesGenentech 320)
Novartis 5
Roche,Genentech,Novartis
Asthma June 20, 2003
173 Gaster 609 622 688 Astellas Pharma Gastrointestinal disorders 1985
174 Lunesta 601 565 327 Sepracor Insomnia Dec. 15, 2004
175 Lamisil group 595 978 1,133 Novartis Fungal infections Dec. 30, 1992
-
8/9/2019 Top 500 Medicines Pharma
14/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
14
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
175 Gonal-f
Note: Serono wasacquired by MerckKGaA Jan. 5, 2007.
595 533(Serono)
547(Serono)
Merck KGaA Infertility Oct. 20, 1995
177 Avandamet 584 408 350 GlaxoSmithKline Type 2 diabetes Oct. 10, 2002
178 Sutent 581 219 0 Pfizer Cancer Jan. 26, 2006
179 Avodart 570 432 258 GlaxoSmithKline Benign prostatichyperplasia
Nov. 20, 2001
179 Follistim/Puregon
Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences alongwith Follistim/PuregonNov. 19, 2007.
Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughs
sales are an actualfigure for the re-mainder of 2007.
570(estimate)
Akzo Nobel 513(estimate)
Schering-Plough57
527(Akzo Nobel)
487(Akzo Nobel)
Akzo Nobel andSchering-Plough
Infertility Sept. 29, 1997/May 3, 1996
181 Strattera 569 579 552 Eli Lilly Attention-deficithyperactivity disorder
Nov. 26, 2002
182 Caduet 568 370 185 Pfizer Cholesterol andhypertension
Jan. 30, 2004
183 Levitra 553Bayer 455
GlaxoSmithKline98
517
Bayer 431
GlaxoSmithKline86
436
Bayer 356
GlaxoSmithKline80
Bayer andGlaxoSmithKline
Erectile dysfunction March 6, 2003
184 Serevent 538 582 660 GlaxoSmithKline Asthma Feb. 4, 1994
185 Amaryl 537 618 928 Sanofi-Aventis Type 2 diabetes Nov. 30, 1995
185 Cancidas 537 530 570 Merck & Co. Fungal infections Jan. 26, 2001187 Synthroid 533 534 554 Abbott Laboratories Hypothyroidism 1955
188 Zoloft 531 2,110 3,256 Pfizer Depression Dec. 30, 1991
189 Basen 528 557 636 TakedaPharmaceutical
Hyperglycemia 1994
190 Xenical 527 578 529 Roche Obesity July 29, 1998
191 RotaTeq 525 163 0 Merck & Co. Rotavirus gastroenteritis Feb. 3, 2006
191 Cipro/Ciprobay 525
Bayer 525
Schering-PloughNA
814
Bayer 703
Schering-Plough111
866
Bayer 720
Schering-Plough146
Bayer Bacter ial infect ions Oct. 22, 1987/1987
193 Relenza 524 182 NA GlaxoSmithKline Influenza June 1999
194 Concor (bisoprolol) 520 497 478 Merck KGaA Hypertension July 31, 1992195 Cardura 506 538 586 Pfizer Hypertension Nov. 2, 1990
196 Vasotec andVaseretic
495 547 623 Merck & Co. Hypertension Dec. 24, 1985, andDec. 24, 1985
196 Mirena
Note: 2006 figure ispro forma for Bayerafter Schering AGproducts acquisitionas of June 23, 2006.
495 413 333(Schering AG)
Bayer Contraception Dec. 6, 2000
198 Xopenex InhalationSolution
487 543 411 Sepracor Bronchospasm March 25, 1999
-
8/9/2019 Top 500 Medicines Pharma
15/69
15
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
199 Claritin 481Schering-Plough391
Shionogi 90
428Schering-Plough356
Shionogi 72
451Schering-Plough371
Shionogi 80
Schering-Plough andShionogi
Allergic rhinitis April 12, 1993
200 Maxalt 467 406 348 Merck & Co. Migraine June 30, 2002
201 Trizivir 466 536 606 GlaxoSmithKline HIV infection Nov. 14, 2000
202 Sensipar 463 321 157 Amgen Hypercalcemia March 8, 2004
203 Tysabri 462Biogen Idec 230
Elan 232
64Biogen Idec 36
Elan 28
16Biogen Idec 5
Elan 11
Biogen Idec andElan
Multiple sclerosis Nov. 23, 2004
204 Xatral 457 484 450 Sanofi-Aventis Benign prostatichypertrophy
January 2000
205 Valcyte andCymevene
452 407 328 Roche Cytomegalovirus retinitis March 29, 2001, and NA
206 Thalomid 447 433 388 Celgene Erythema nodosumleprosum
July 16, 1998
207 Humatrope 441 416 414 Eli Lilly Growth failure March 9, 1991
208 Skelaxin 440 415 345 King Pharmaceuticals Musculoskeletal conditions NA209 Zithromax and Zmax 438 638 2,025 Pfizer Bacter ial infect ions Nov. 4, 1991, and
June 10, 2005
210 Zomig 434 398 352 AstraZeneca Migraine July 8, 1997
211 Depakine 433 413 436 Sanofi-Aventis Epilepsy NA
211 BeneFix 433 358 343 Wyeth Hemophilia Feb. 11, 1997
213 Neurontin 431 496 639 Pfizer Seizures Dec. 29, 1993
214 Mobic 428Boehringer 326
Daiichi 102
901
Boehringer 794
Daiichi 107
2,501
Abbott 1,232
Boehringer 1,163
Daiichi Sankyo106
Boehringer IngelheimandDaiichi Sankyo
Osteoarthritis andrheumatoid arthritis
Feb. 27, 1996
215 Fabrazyme 424 359 305 Genzyme Fabrys disease August 2001
215 Nutropin andNutropin AQ
Note: Genentechreports U.S. sales thatare also recordedby parent companyRoche.
424Roche 392(includesGenentech 371)
Ipsen 32(Nutropin AQonly)
432Roche 412(includesGenentech 378)
Ipsen 20(Nutropin AQonly)
405Roche 397(includesGenentech 370)
Ipsen 8(Nutropin AQonly)
Roche,Genentech,Ipsen
Growth failure Nutropin: Nov. 17, 1993(U.S. approval)
Nutropin AQ: Dec. 29,1995 (U.S. approval)
217 Taxol 422 563 747 Bristol-Myers Squibb Cancers Dec. 29, 1992
217 Androgel 422 377 328 Solvay Hypogonadism June 14, 2000(U.S. approval)
219 Diflucan 415 435 498 Pfizer Fungal infections Jan. 29, 1990
220 Magnevist
Note: 2006 figure ispro forma for Bayerafter Schering AGproducts acquisitionas of June 23, 2006.
413 443 450(Schering)
Bayer Magnetic resonanceimaging
June 2, 1988
220 Tegretol 413 391 393 Novartis Seizures March 12, 1972
222 Proscar 411 619 741 Merck & Co. Benign prostatichypertrophy
June 19, 1992
223 Glucobay 409 422 404 Bayer Type 2 diabetes NA
224 Propecia 405 352 292 Merck & Co. Hair loss Dec. 19, 1997
225 Nasacort 403 388 381 Sanofi-Aventis Allergic rhinitis May 21, 2000
225 Pletal 403 360 NA OtsukaPharmaceutical
Cardiac ischemiccomplications
1988 (Japan approval)
-
8/9/2019 Top 500 Medicines Pharma
16/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
16
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
225 Pulmozyme
Note: Genentechreports U.S. sales thatare also recordedby parent companyRoche.
403
Roche 403(includesGenentech 223)
363
Roche 363(includesGenentech 199)
328
Roche 328(includesGenentech 186)
Roche andGenentech
Cystic fibrosis Dec. 30, 1993
228 Aromasin 401 320 247 Pfizer Breast cancer Oct. 21, 1999229 Flonase/Flixonase 398 622 1,312 GlaxoSmithKline Allergic rhinitis Oct. 9, 1994/
Sept. 15, 1995
230 Prandin andNovoNorm
395 365 306 Novo Nordisk Type 2 diabetes Prandin: Dec. 22, 1997(U.S. approval)NovoNorm:Aug. 17, 1998(EU approval)
231 Zofran 392 1,694 1,674 GlaxoSmithKline Nausea and vomiting Dec. 31, 1992
231 Lumigan franchise 392 328 268 Allergan Intraocular pressure March 16, 2001
233 Abraxane 387
Abraxis 325
AstraZeneca 62
193
Abraxis 175
AstraZeneca 18
134
Abraxis 134
AstraZeneca 0
Abraxis andAstraZeneca
Breast cancer February 2005(U.S. launch)
233 NuvaRing
Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences alongwith NuvaRingNov. 19, 2007.
Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughssales are an actualfigure for the re-mainder of 2007.
387(estimate)
Akzo Nobel 342(estimate)Schering-Plough45
292
(Akzo Nobel)174(Akzo Nobel)
Akzo Nobel andSchering-Plough
Contraception June 12, 2001
235 Aggrenox 381 308 236 Boehringer Ingelheim Stroke Nov. 22, 1999
235 Ritalin and Focalin 381Novartis 375
Celgene 6
337Novartis 330
Celgene 7
212Novartis 208
Celgene 4
Novartis and Celgene Attention-deficithyperactivity disorder
Dec. 5, 1955, andNov. 13, 2001
237 Adenoscan 376 371 353 Astellas Pharma Myocardial perfusionscintigraphy
May 19, 1999
238 Opalmon 373 338 326 Ono Pharmaceutical Thromboangiitis obliterans 1988
239 Nexavar 370
Bayer 370
Onyx NA
178
Bayer 178
Onyx NA
NA
Bayer NA
Onyx NA
Bayer andOnyxPharmaceuticals
Advanced kidney cancerand liver cancer
Dec. 21, 2005(U.S. launch)
240 Restasis 369
Allergan 345
Inspire 24
286
Allergan 270
Inspire 16
198
Allergan 191
Inspire 7
Allergan andInspirePharmaceuticals
Dry eye Dec. 23, 2002
241 Fraxiparine 368 408 422 GlaxoSmithKline Deep-vein thrombosis NA
242 Rapamune 365 337 300 Wyeth Renal transplant rejection Sept. 15, 1999
242 Glucophage/metformin franchise
365Merck KGaA 365(Glucophage/metforminproducts)
BMS NA(Glucophagefranchise)
493(estimate)
Merck KGaA 398(Glucophage/metforminproducts)
BMS 95(estimate forGlucophagefranchise)
579
Merck KGaA 407(Glucophage/metforminproducts)
BMS 172(Glucophagefranchise)
Merck KGaA andBristol-Myers Squibb
Type 2 diabetes Dec. 29, 1994
-
8/9/2019 Top 500 Medicines Pharma
17/69
17
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
244 Foradil 362 331 332 Novartis Asthma Nov. 17, 1999
245 Zovirax 361
GlaxoSmithKline214
Biovail 147
352
GlaxoSmithKline240
Biovail 112
358
GlaxoSmithKline262
Biovail 96
GlaxoSmithKline andBiovail
Herpes March 30, 1986
246 Viramune 359 378 395 Boehringer Ingelheim HIV infection June 22, 2000
246 rhBMP-2 359 308 236 Wyeth Tibia fractures Sept. 17, 2002
248 Exjade 357 143 2 Novartis Iron overload Nov. 2, 2005(U.S. approval)
249 Espo and NESP 356 344 368 Kirin Brewery Anemia Espo: 1990(Japan launch)
NESP: 2007(Japan launch)
250 Rhinocort 354 360 387 AstraZeneca Allergic rhinitis Feb. 14, 1994
250 Kytril
Note: Chugai reportsJapan sales thatare also recordedby parent company
Roche.
354
Roche 354(includesChugai 116)
415
Roche 415(includesChugai 110)
417
Roche 417(includesChugai 104)
Roche andChugaiPharmaceutical
Nausea and vomiting January 1992
252 Mucosta 353 339 NA OtsukaPharmaceutical
Gastritis and ulcers 1990 (Japan launch)
253 Alphagan P,Alphagan,Combigan
341 296 277 Allergan Intraocular pressure March 16, 2001,Sept. 6, 1996,fourth-quarter 2003
254 AmBisome 339
Gilead 263
Astellas 76
311
Gilead 223
Astellas 88
310
Gilead 221
Astellas 89
Gilead Sciences andAstellas Pharma
Fungal infections Aug. 11, 1997
255 Neutrogin
Note: Chugai reportsJapan sales thatare also recordedby parent company
Roche.
338
Roche 338(includesChugai 335)
316
Roche 316(includesChugai 309)
303
Roche 303(includesChugai 276)
Roche andChugaiPharmaceutical
Neutropenia Oct. 4, 1991
256 Zeffix 336 324 290 GlaxoSmithKline Hepatitis B Dec. 8, 1998
256 Loxonin 336 309 290 Daiichi Sankyo Inflammation Feb. 17, 1978
256 Zantac 336 464(GSK)
495
GSK 488
Daiichi Sankyo 7
GlaxoSmithKline Gastrointestinal disorders June 9, 1983
259 ReFacto 335 306 268 Wyeth Hemophilia April 14, 2003
260 Rocephin
Note: Chugai reportsJapan sales thatare also recordedby parent companyRoche.
333
Roche 333(includesChugai 49)
347
Roche 347(includesChugai 47)
773
Roche 773(includesChugai 46)
Roche andChugaiPharmaceutical
Bacterial infections Dec. 21, 1984
-
8/9/2019 Top 500 Medicines Pharma
18/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
18
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
261 Integrilin
Notes:Schering-Ploughis marketer in U.S.and other non-EUareas.
Millenniumreportedco-promotionrevenue from Jan.1, 2005, throughSept. 1, 2005;thereafter royaltyand strategicalliance revenuewere recorded.
GlaxoSmithKline isEU marketer.
332
Schering-Plough332Millennium NA
GlaxoSmithKline
NA
329
Schering-Plough329
Millennium NA
GlaxoSmithKline
NA
439
Schering-Plough315
Millennium 124
GlaxoSmithKline
NA
Schering-Plough,MillenniumPharmaceuticals,GlaxoSmithKline
Acute coronary syndrome June 1998 (U.S. launch)
262 Arcoxia 329 265 218 Merck & Co. Osteoarthritis andrheumatoid arthritis
April 15, 2002
263 Xanax andXanax XR
325 316 409 Pfizer Anxiety disorder andpanic disorder
Nov. 27, 1985, andJan. 17, 2003
264 Ultravist
Notes: Bayer 2006figure is pro formaafter Schering AGproducts acquisitionas of June 23, 2006.
322 304 340(Schering AG) Bayer Imaging/various May 11, 1999
264 Decapeptyl 322 304 289 Ipsen Advanced metastaticprostate cancer
1986 (France launch)
266 Activase, TNKase,Cathflo Activase
Note: Genentechreports U.S. salesthat are recordedby parent companyRoche.
318
Roche 318(includesGenentech 268)
302
Roche 302(includesGenentech 243)
258
Roche 258(includesGenentech 218)
Roche andGenentech
Myocardial infarction Feb. 17, 1996,June 2, 2000, andSept. 4, 2001
267 Relpax 315 286 233 Pfizer Migraine June 14, 2001
268 Epivir 312 404 522 GlaxoSmithKline HIV infection Nov. 17, 1995
268 Omnipaque 312 315 347 Daiichi Sankyo Contrast enhancement Dec. 26, 1985(U.S. approval)
270 Venofer 311 309 226 Daiichi Sankyo Iron deficiency anemia Nov. 7, 2000
271 Crixivan and Stocrin 310 327 348 Merck & Co. HIV infection March 13, 1996,and 1999
272 Tenormin 308 320 352 AstraZeneca Hypertension Aug. 19, 1981
273 Ebixa 304 250 203 H. Lundbeck Alzheimers disease May 23, 2002
273 Remeron
Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences along
with RemeronNov. 19, 2007.
Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughssales are an actualfigure for the re-mainder of 2007.
304(estimate)
Akzo Nobel 271(estimate)
Schering-Plough
33
347(Akzo Nobel)
388(Akzo Nobel)
Akzo Nobel andSchering-Plough
Depression June 15, 2000
275 Hepsera 303 231 187 Gilead Sciences Hepatitis B Sept. 20, 2002
276 Zestril 295 307 332 AstraZeneca Hypertension Dec. 30, 1987
-
8/9/2019 Top 500 Medicines Pharma
19/69
19
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
277 Iopamiron
Notes: Bayer 2006figure is pro formaafter Schering AGproducts acquisitionas of June 23, 2006.
289 303 332(Schering)
Bayer Imaging/uroangiography NA
278 Flomox 286 306 341 Shionogi Bacterial infections June 1997279 Cubicin 285 190 113 Cubist
PharmaceuticalsBacterial infections Sept. 12, 2003
280 Agenerase andLexiva
282 262 224 GlaxoSmithKline HIV infection April 15, 1999, andOct. 20, 2003
281 Miacalcin/Miacalcic
281 339 365 Novartis Osteoporosis July 3,1986/NA
282 Vaqta,Recombivax HB,Comvax
280 249 195 Merck & Co. Hepatitis Vaqta: May 1996(U.S. launch)Recombivax HB:Aug. 27, 1999(U.S. approval)Comvax: January 1997(U.S. launch)
283 Radicut 279 286 325 Mitsubishi TanabePharma
Cerebral infarction June 2001(Japan launch)
284 Rebetol 277 311 331 Schering-Plough Hepatitis C June 4, 2002
285 Baraclude 275 83 12 Bristol-Myers Squibb Hepatitis B March 29, 2005
286 Tobi/Tobramycin
Note: Chiron andTobi were acquiredby Novartis in April2006.
273(Novartis)
245Novartis 177
Chiron 68(estimate)
233(Chiron)
Novartis Cystic fibrosis infection Tobi: Dec. 22, 1997(U.S. approval)
287 Onon 271 268 265 Ono Pharmaceutical Bronchial asthma andallergic rhinitis
Oct. 1, 1999
287 Plendil 271 275 360 AstraZeneca Hypertension July 27, 1995
287 Creon 271 262 222 Solvay Pancreatic exocrineinsufficiency
NA
290 Fuzeon 267 249 208 Roche HIV infection March 27, 2003(U.S. launch)
290 Thrombin-JMI 267 247 221 King Pharmaceuticals Bleeding during surgery Feb. 24, 1995
292 Velcade
Note: Millenniumfigures are netproduct sales andexclude strategicalliance revenueand royaltiesassociated withnon-U.S. marketer,J&Js OrthoBiotech.
265
Millennium 265
J&J NA
221
Millennium 221
J&J NA
192
Millennium 192
J&J NA
MillenniumPharmaceuticalsandJohnson & Johnson
Multiple myeloma May 13, 2003(U.S. approval)
293 ProQuad 264 235 NA Merck & Co. Measles, mumps, rubella Sept. 6, 2005
294 Diprivan
Note: Abraxis
acquired U.S. rightsto Diprivan fromAstraZeneca inJune 2006.
263+
AstraZeneca 263
Abraxis NA
304+
AstraZeneca 304
Abraxis NA
369(AstraZeneca)
AstraZeneca andAbraxis
Anesthesia Oct. 2, 1989
295 DuoNeb
Note: MerckKGaAs Dey LPalong with DuoNebwere acquired Oct.2, 2007, by Mylan;DuoNeb productexclusivity was lostin July 2007.
260(estimate)
Merck KGaA 218(estimate)
Mylan 42(estimate)
369(Merck KGaA)
344(Merck KGaA)
Merck KGaA andMylan
Bronchospasm March 21, 2001
296 Caelyx 257 206 181 Schering-Plough Cancers June 21, 1996
-
8/9/2019 Top 500 Medicines Pharma
20/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
20
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
297 Zanidip/Lercadip/lercanidipine
256 235 194 Recordati Hypertension NA
298 Clarith 255 273 275 TaishoPharmaceutical
Bacterial infections NA
298 Angiomax 255 201 150 The Medicines Co. Percutaneous coronaryinterventions
January 2001(U.S. launch)
300 Coniel 254 263 281 Kyowa Hakko Kogyo Hypertension NA
301 Urso franchise 248
MitsubishiTanabe 171
Axcan 77
221
MitsubishiPharma 159
Axcan 62
223
MitsubishiPharma 176
Axcan 47
Mitsubishi TanabePharma andAxcan Pharma
Primary bil iary cirrhosis July 1962 (Japan)May 1998 (U.S. launch)
302 Synvisc 242 234 219 Genzyme Osteoarthritis Aug. 13, 1997
303 Actiq 240 578 412 Cephalon Cancer pain Nov. 4, 1998
303 Diane
Notes: Bayer 2006figure is pro formaafter Schering AGproducts acquisitionas of June 23, 2006.
240 240 236(Schering AG)
Bayer Contraception NA
305 Iressa 238 237 273 AstraZeneca Nonsmall cell lung cancer May 5, 2003
305 Hycamtin 238 226 198 GlaxoSmithKline Cancers May 29, 2000
307 Zostavax 236 39 0 Merck & Co. Shingles May 25, 2006
308 Omnicef 235 637 495 Abbott Laboratories Bacterial infections Dec. 4, 1997
309 Intron A 233 237 287 Schering-Plough Hepatitis June 5, 1990
309 Allelock 233 210 199 Kyowa Hakko Kogyo Allergic rhinitis Dec. 22, 2000
311 Orencia 231 89 0 Bristol-Myers Squibb Rheumatoid arthritis Dec. 23, 2005
312 Xyzal 230 196 173 UCB Allergic rhinitis Aug. 28, 2001
313 M-M-R II 228 NA NA Merck & Co. Measles, mumps, andrubella
NA
314 WelChol 227 187 148 Daiichi Sankyo Cholesterol May 27, 2004
315 Saizen
Note: Merck KGaAacquired Seronoalong with SaizenJan. 5, 2007.
224 209(Serono)
206(Serono)
Merck KGaA Growth failure Oct. 8, 1996
316 Subutex/Subuxone 220 203 197 Schering-Plough Opiate addiction Oct. 8, 2002(U.S. approvals)
317 Ziagen 218 234 272 GlaxoSmithKline HIV infection Dec. 17, 1998
318 Aloxi 216(estimate)
251 249 MGI Pharma Nausea and vomiting July 25, 2003
319 Visudyne 215 354 484 Novartis Age-related maculardegeneration
April 12, 2000
319 Myslee 215 194 171 Astellas Pharma Insomnia Dec. 13, 2000
321 Faslodex 214 186 140 AstraZeneca Breast cancer April 25, 2002
322 Raptiva
Notes: Total2007, 2006 and2005 figureswere reported byRaptiva developerXoma.
Genentech reportsU.S. sales that arerecorded by parentcompany Roche.
Merck KGaAacquired SeronoJan. 5, 2007.
213
Roche 107 (viaGenentech 107)
Merck KGaA106
160
Roche 90 (viaGenentech 90)
Serono 70
113
Roche 79 (viaGenentech 79)
Serono 34
Genentech andMerck KGaA
Psoriasis November 2003(U.S. launch)
323 Artist 211 193 182 Daiichi Sankyo Congestive heart failure NA
-
8/9/2019 Top 500 Medicines Pharma
21/69
21
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
324 Serc 206 200 167 Solvay Menieres Syndrome NA
325 Emend 204 131 87 Merck & Co. Nausea and vomiting March 26, 2003
325 Vancocin 204 167 126 ViroPharma Bacterial infections April 15, 1986(U.S. approval)
327 Coumadin 201 220 212 Bristol-Myers Squibb Deep-vein thrombosis NA
327 Myozyme 201 59 4 Genzyme Pompe disease NA
327 Remodulin 201 153 110 United Therapeutics Pulmonary arterialhypertension
May 21, 2002(U.S. launch)
327 Livial
Notes:Schering-Ploughacquired AkzoNobels OrganonBioSciences alongwith LivialNov. 19, 2007.
Akzo Nobel 2007sales are estimatedfrom Jan. 1, 2007,thru Nov. 18, 2007.Schering-Ploughs
sales are an actualfigure for the re-mainder of 2007.
201(estimate)
Akzo Nobel 177(estimate)
Schering-Plough24
207(Akzo Nobel)
211(Akzo Nobel)
Akzo Nobel andSchering-Plough
Menopausal symptoms March 1997
331 Arixtra 200 116 48 GlaxoSmithKline Deep-vein thrombosis Dec. 7, 2001
332 Cefzon 198 255 293 Astellas Pharma Bacterial infections 1991
332 Cardizem LA
Note: Abbottacquired KosPharmaceuticals inDecember 2006
198(estimate)
Abbott 129(estimate)
Biovail 69
162(estimate)
Kos 105(estimate)
Abbott NA
Biovail 57
132
Kos 70
Biovail 62
Abbott Laboratoriesand Biovail
Hypertension Feb. 6, 2003
334 Amitiza 196(Takeda)
57(Takeda)
0 TakedaPharmaceuticaland Sucampo
Pharmaceuticals
Constipation April 25, 2006(U.S. launch)
335 Gasmotin 195 185 163 Dainippon Sumitomo Gastrointestinal disorders 1998
335 Hyalein 195 179 169 SantenPharmaceutical
Corneal disease June 1995(Japan launch)
337 Invanz 190 139 94 Merck & Co. Bacterial infections Nov. 9, 2001
337 Timoptic/Timoptoland Timoptic-XE/Timoptol XE
190
Merck & Co. 120(Timoptic andTimoptic XE)
Santen 70(Timoptol andTimoptol XE)
198
Merck & Co. 127(Timoptic andTimoptic XE)
Santen 71(Timoptol andTimoptol XE)
211
Merck & Co. 138(Timoptic andTimoptic XE)
Santen 73(Timoptol andTimoptol XE)
Merck & Co. andSantenPharmaceutical
Intraocular pressure andglaucoma
Timoptic: Aug. 17, 1978(U.S. approval)Timoptic-XE: Nov. 4,1993 (U.S. approval)Timoptol: September1981 (Japan launch)Timoptol XE: November1999 (Japan launch)
339 Euthyrox products 186 176 156 Merck KGaA Hypothyroidism NA
340 Anplag 183 167 177 Mitsubishi TanabePharma
Chronic arterial occlusion October 1993 (launch)
341 Rotarix 182 88 NA GlaxoSmithKline Rotavirus infection Feb. 27, 2006
341 Elaprase 182 24 0 Shire PharmaceuticalsGroup
Hunter syndrome July 24, 2006(U.S. approval)
341 Bonalon 182 138 119 Teijin Osteoporosis August 2001(Japan launch)
344 Enablex/Emselex 179 114 46 Novartis Overactive bladder Enablex: Dec. 22, 2004(U.S. appoval)Emselex: Oct. 27, 2004(EU approval)
345 Mycamine/Funguard
178 165 152 Astellas Pharma Fungal infections March 16, 2005/December 2002
346 Dysport 176 155 127 Ipsen Cervical dystonia 1991 (U.K. launch)
-
8/9/2019 Top 500 Medicines Pharma
22/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
22
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
346 Elidel 176 179 268 Novartis Atopic dermatitis Dec. 13, 2001
346 Herbesser 176 180 188 Mitsubishi TanabePharma
Hypertension February 1974
346 Pentasa 176 138 136 Shire PharmaceuticalsGroup
Ulcerative colitis May 11, 1997
346 Calcichew 176
Nycomed 122
Shire 54
174
Nycomed 128
Shire 46
145
Nycomed 106
Shire 39
Nycomed and
Shire PharmaceuticalsGroup
Osteoporosis NA
351 Thymoglobulin/Lymphoglobuline
175 150 128 Genzyme Renal transplant rejection Dec. 30, 1998/NA
352 Kinedak 174 173 212 Ono Pharmaceutical Peripheral neuropathy NA
352 Influvac 174 162 137 Solvay Influenza 2003 (launch)
354 Teveten franchise
Notes: Abbottacquired KosPharmaceuticals inDecember 2006.
Biovailtransferredproduct rights forTeveten to Kos inMay 2005.
172(estimate)
Solvay 145
Abbott 27(estimate)
154(estimate)
Solvay 130
Kos 24(estimate)
Abbott NA
153
Solvay 125
Kos 22
Biovail 6
Solvay and AbbottLaboratories
Hypertension Dec. 22, 1997(U.S. approval)
355 Vectibix 170 39 0 Amgen Colorectal cancer Sept. 27, 2006
356 Kadian 168 138 102 Alpharma Pain July 3, 1996
357 Benet 165 162 157 TakedaPharmaceutical
Osteoporosis May 2002(Japan launch)
358 Protopic 164 147 144 Astellas Pharma Dermatitis June 16, 1999
358 Tanakan 164 178 166 Ipsen Neurological and vasculardisorders
1975 (France launch)
360 Sprycel 158 25 0 Bristol-Myers Squibb Leukemia June 28, 2006
361 Tussionex 156 144 148 UCB Cough Dec. 31, 1987
362 Sigmart 153 154 165 ChugaiPharmaceutical
Angina pectoris 1984
363 Ceredist 152 145 137 Mitsubishi TanabePharma
Spinal cerebellardegeneration
September 2000(Japan launch)
364 Azilect 151
Teva 120
Lundbeck 31
57
Teva 44
Lundbeck 13
1+
Teva NA
Lundbeck 1
Teva PharmaceuticalIndustries andH. Lundbeck
Parkinsons disease March 2005(Israel launch)
365 Wellbutrin IR and SR 150
GSK 150
Biovail NA
204
GSK 204
Biovail NA
184
GSK 184
Biovail NA
GlaxoSmithKline andBiovail
Depression Dec. 30, 1985, andOct. 4, 1996
365 Eligard 150
Astellas 92
MediGene 30
QLT 28
123
Astellas 59
MediGene 42
QLT 22
70
Astellas 26
MediGene 27
QLT 17
Astellas Pharma,MediGene, QLT
Prostate cancer May 2004(Germany launch)
365 Trasylol 150 210 315 Bayer Perioperative blood loss Dec. 29, 1993
368 Loestrin 24 FE 149 44 0 Warner Chilcott Prevention of pregnancy Feb. 17, 2006(U.S. approval)
369 Meropen 148 143 141 Dainippon Sumitomo Bacterial infections NA
370 Prorenal 145 138 126 Dainippon Sumitomo Peripheral circulat ion 1988
371 Tanatril 144 145 147 Mitsubishi TanabePharma
Hypertension December 1993
371 Replagal 144 118 41 Shire PharmaceuticalsGroup
Fabrys disease Aug. 3, 2001
371 Marinol 144 145 115 Solvay Nausea and vomiting 1987 (U.S. launch)
-
8/9/2019 Top 500 Medicines Pharma
23/69
23
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
374 Somatuline 142 126 112 Ipsen Acromegaly 1995 (France launch)
375 Durotep 139 141 135 Kyowa Hakko Kogyo Cancer pain October 2001
375 Elcitonin 139 138 152 Asahi Kasei Osteoporosis NA
377 Nootropil 138 136 141 UCB Cognitive disorders NA
377 Tygacil 138 72 10 Wyeth Bacterial infections June 15, 2005
379 Fentora 135 29 0 Cephalon Cancer pain Sept. 25, 2006
380 Boostrix 132 120 NA GlaxoSmithKl ine Diphther ia, tetanus, andpertussis
May 3, 2005
381 Gran 130 134 138 Kirin Brewery Leukopenia 1991 (Japan launch)
382 Venoglobulin-IH 129 132 141 Mitsubishi TanabePharma
Immunological conditions January 1992
383 Taclonex 127 60 0 Warner Chilcott Psoriasis vulgaris April 3, 2006(U.S. launch)
383 Avinza
Note: Kingacquired all rightsto Avinza in theUnited States, itsterritories andCanada fromLigand Feb. 26,2007.
127King 109
Ligand 18
137King 0
Ligand 137
113King 0
Ligand 113
King Pharmaceuticalsand LigandPharmaceuticals
Pain March 20, 2002
385 Actovegin 126 108 88 Nycomed Metabolic stimulation NA
385 Rozerem 126 103 30 TakedaPharmaceutical
Insomnia Sept. 26, 2005(U.S. launch)
387 Isovorin 125 140 128 TakedaPharmaceutical
Tumors October 1999(Japan launch)
387 Onealfa 125 118 120 Teijin Osteoporosis NA
389 Kremezin 124 122 130 Daiichi Sankyo Renal failure December 1991
389 Aldurazyme 124 96 76 BioMarin/Genzyme(joint venture)
Mucopolysaccharidosis April 30, 2003
391 Maxipime 123 160 140 Elan Bacterial infections Jan. 18, 1996
391 Alfarol 123 125 135 ChugaiPharmaceutical
Osteoporosis 1981
391 Seltouch 123 127 137 TakedaPharmaceutical
Pain September 1993(Japan launch)
394 Flumarin 122 133 156 Shionogi Bacterial infections NA
394 Percocet 122 103 111 EndoPharmaceuticalsHoldings
Pain June 25, 1999
394 Smecta 122 110 93 Ipsen Diarrhea and pain 1977 (France launch)
397 Sunrythm 121 117 119 Daiichi Sankyo Arrhythmia NA
398 Frandol 120 123 127 Astellas Pharma Angina pectoris NA
399 Vancomycin 117 117 111 Shionogi Bacterial infections NA
399 Imunace 117 117 111 Shionogi Cancers NA
399 Dacogen 117(estimate)
36 0 MGI Pharma Myelodysplastic syndrome May 26, 2006(U.S. launch)
402 Depas 116 113 126 Mitsubishi TanabePharma
Anxiety March 1984 (launch)
402 Doryx 116 102 96 Warner Chilcott Bacterial infections July 22, 1985(U.S. approval)
404 Palux 114 112 120 TaishoPharmaceutical
Ulcers 1999
405 Ebastel 111 114 113 Dainippon Sumitomo Allergies NA
405 Mucosolvan 111 115 117 Teijin Expectorant NA
407 Luvox 110 111 103 Astellas Pharma Depression April 8, 2003
407 Onon Dry Syrup 110 114 94 Ono Pharmaceutical Pediatric bronchialasthma
Oct. 1, 1999
409 Metadate CD/Equasym XL
108 93 70 UCB Attention-deficithyperactivity disorder
April 3, 2001/February 2005
-
8/9/2019 Top 500 Medicines Pharma
24/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
24
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
410 Opana andOpana ER
107 7 0 EndoPharmaceuticalsHoldings
Pain July 24, 2006(U.S. launches)
411 Depakene 105 102 102 Kyowa Hakko Kogyo Seizures NA
412 Liple 104 102 113 Mitsubishi TanabePharma
Chronic arterial occlusion November 1988(launch)
413 Maintate 103 99 102 Mitsubishi TanabePharma
Hypertension NA
413 Exforge 103 10 0 Novartis Hypertension Jan. 18, 2007(EU approval date)
415 Calblock 102 88 64 Daiichi Sankyo Hypertension 2003
415 Fosrenol 102 45 54 Shire PharmaceuticalsGroup
Phosphorus level reduction Oct. 26, 2004
415 Tykerb 102 0 0 GlaxoSmithKline Breast cancer March 13, 2007
418 Avandaryl 100 84 0 GlaxoSmithKline Type 2 diabetes Nov. 23, 2005
418 Levoxyl 100 112 140 King Pharmaceuticals Hypothyroidism May 25, 2001
418 Rinderon 100 101 102 Shionogi Ocular surface disorders NA
421 HANP 98 92 86 Daiichi Sankyo Acute heart failure NA
422 Sermion 95 102 114 Mitsubishi Tanabe
Pharma
Cerebral circulation June 1988
(Japan launch)422 Urief 95
Daiichi 54
Kissei 41
37
Daiichi 23Kissei 14
0 Daiichi Sankyo andKissei Pharmaceutical
Dysuria May 2006
422 Ethyol
Note: MedImmune2007 figure is afirst-half estimate;MedImmune wasacquired alongwith Ethyol byAstraZeneca inJune 2007.
95(estimate)
MedImmune 52(estimate)
AstraZeneca 43
87(MedImmune)
95(MedImmune)
AstraZeneca andMedImmune
Renal toxicity reduction Dec. 8, 1995
425 Flivas 94 93 91 Asahi Kasei Benign prostatichyperplasia
NA
425 Suvenyl 94 78 69 ChugaiPharmaceutical
Rheumatoid arthritis March 2000
425 Bezatol 94 98 106 Kissei Pharmaceutical Hyperlipidemia April 1991
428 Zoton 93 131 376 Wyeth Gastrointestinal disorders 1994
429 Colazal 92 103 110 Salix Pharmaceuticals Ulcerative colitis July 18, 2000
429 Plan B
Notes: 2007 includesRx and OTC salesas the two segmentswere not brokendown by Barr.
Barr changed froma June 30 fiscal yearfor 2006 and 2005 to
a Dec. 31 year endfor 2007.
92 NA NA Barr Pharmaceuticals Contraception July 28, 1999
431 Prexige 91 47 8 Novartis Osteoarthritic pain 2005 (Australia, Brazil,New Zealand,U.K. launches)
432 Venilon 89 94 93 Teijin Severe infectious diseases February 1980(Japan launch)
432 Noxafil 89 19 NA Schering-Plough Fungal infections Sept. 15, 2006(U.S. approval)
434 Zelnorm/Zelmac 88 561 417 Novartis Irritable bowel syndrome March 19, 2002/Oct. 30, 2001
434 TachoSil 88 84 64 Nycomed Tissue management NA
434 Glovenin 88 86 85 TakedaPharmaceutical
Blood disorders November 1991(Japan launch)
-
8/9/2019 Top 500 Medicines Pharma
25/69
25
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
434 Talion 88 70 64 Mitsubishi TanabePharma
Allergic rhinitis October 2000 (launch)
438 Aggrastat
Notes: Medicureacquired AggrastatU.S. rights from MGI
Aug. 8, 2006.
MGI acquired Aggra-stat U.S. rights fromGuilford Pharma-ceuticals in October2005.
87+
Merck 87
Medicure NA
90+
Merck 86
MGI 4
Medicure NA
99(estimate)
Merck 88
Guilford 9(estimate)MGI Pharma 2
Medicure 0
Merck & Co. andMedicure
Acute coronary syndrome May 1998 (U.S. launch)
438 Ultram ER 87+
Biovail 87
J&J NA
54+
Biovail 54
J&J NA
0 Biovail andJohnson & Johnson
Pain Feb. 21, 2006 (U.S. launch)
438 Meptin 87 37 NA OtsukaPharmaceutical
Bronchial musclerelaxation
1980 (Japan launch)
438 Farmorubicin andAdriacin
87 86 95 Kyowa Hakko Kogyo Cancers NA
442 Oxis 86 88 91 AstraZeneca Asthma March 4, 2001
442 Azactam 86 78 58 Elan Bacterial infections Dec. 31, 1986
442 Naglazyme 86 47 6 BioMarinPharmaceutical
Mucopolysaccharidosis May 31, 2005
442 Janumet 86 0 0 Merck & Co. Type 2 diabetes March 30, 2007(U.S. approval)
446 Pansporin 84 109 127 TakedaPharmaceutical
Bacterial infections February 1981(Japan launch)
446 Intal 84
Astellas 70
King 14
94
Astellas 79
King 15
96
Astellas 84
King 12
Astellas Pharma andKing Pharmaceuticals
Asthma May 29, 1986
448 Nolvadex 83 89 114 AstraZeneca Breast cancer Dec. 30, 1977
449 Tazorac, Zorac,Avage
80 91 87 Allergan Acne, facial wrinkles June 13, 1997,Dec. 12, 1996,
Sept. 30, 2002
449 Campral 80
Merck KGaA 49
Forest 31
79
Merck KGaA 49
Forest 30
70
Merck KGaA 47
Forest 23
Merck KGaA andForest Laboratories
Alcoholism U.S. approval:July 29, 2004U.S. launch:January 2005
451 Sonata 79 86 83 King Pharmaceuticals Insomnia Aug. 13, 1999
452 Dasen 77 81 85 TakedaPharmaceutical
Inflammation November 1968(Japan launch)
452 Rheumatrex 77 69 67 TakedaPharmaceutical
Rheumatoid arthritis August 1999(Japan launch)
452 Vyvanse 77 0 0 Shire PharmaceuticalsGroup
Attention deficithyperactivity disorder
July 27, 2007(U.S. launch)
455 Accolate 76 81 72 AstraZeneca Asthma Sept. 24, 1996
455 Mearubik 76 59 6 Mitsubishi TanabePharma
Measels and Rubellaimmunization
December 2005(launch)
457 Serostim
Note: Serono alongwith Serostim wereacquired by MerckKGaA Jan. 5, 2007.
75 72(Serono)
70(Serono)
Merck KGaA AIDS wasting Aug. 23, 1996
457 Atarax 75 74 67 UCB Anxiety NA
459 Dorner 74 78 85 Astellas Pharma Circulatory disorders 1992
459 Oxarol 74 65 62 ChugaiPharmaceutical
Hyperparathyroidism September 2000
459 Alkeran 74 50 50 Celgene Multiple myeloma,ovarian cancer
May 27, 1974
-
8/9/2019 Top 500 Medicines Pharma
26/69
TOP 500 PRESCRIPTION MEDICINES BY SALES
26
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
459 Frova/Migard 74Endo 52 (Frova)
Menarini 22(Migard)
58
Endo 41 (Frova)
Menarini 17(Migard)
38+
Endo 38 (Frova)
Menarini NA(Migard)
EndoPharmaceuticalsHoldings andMenarini
Migraine Migard: January 2002(EU approval)
Frova: June 2002(U.S. launch)
459 Nisis and Nisisco 74 70 57 Ipsen Arterial hypertension NA
464 Estrace Cream 73 66 54 Warner Chilcott Menopausal symptoms Jan. 31, 1984(U.S. approval)
465 Carbatrol 72 68 72 Shire PharmaceuticalsGroup
Seizures Sept. 30, 1997
465 Efudex/Efudix 72 78 60 ValeantPharmaceuticals
Multiple actinic keratosesand superficial basal cellcarcinoma
Efudex: July 29, 1970(U.S. approval)
467 Neupro 71 14 0 UCB Parkinsons disease Feb. 20, 2006(Europe approval)
467 Forlax 71 63 59 Ipsen Constipation
469 Dogmatyl 70 73 78 Astellas Pharma Ulcers NA
469 Paragard
Note: Barr changedfrom a June 30 fiscal
year for 2006 and2005 to a Dec. 31year end for 2007.
70 NA NA Barr Pharmaceuticals Contraception Nov. 15, 1984
471 Xagrid 69 53 47 Shire PharmaceuticalsGroup
Thrombocythemia November 2004(EU approval)
472 Ranexa 67 18 0 CV Therapeutics Chronic angina March 24, 2006(U.S. launch)
473 OxyContin 66+
Purdue NA
Shionogi 66
52+
Purdue NA
Shionogi 52
43+
Purdue NA
Shionogi 43
Purdue Pharmaand Shionogi
Cancer pain Dec. 12, 1995(U.S. approval)July 7, 2003(Japan launch)
473 Perdipine andPerdipine LA
66 75 89 Astellas Pharma Hypertension 1981 and NA
473 Cefamezin 66 66 75 Astellas Pharma Bacterial infections NA
473 Symlin 66 44 12 AmylinPharmaceuticals
Diabetes March 16, 2005
473 Soliris 66 0 0 AlexionPharmaceuticals
Paroxysmal nocturnalhemoglobinuria
April 2007 (U.S. launch)
473 Atmadisc
Note: SchwarzPharma wasacquired by UCB inDecember 2006.
66 65(Schwarz)
61(Schwarz)
UCB Asthma Aug. 24, 2000
479 Ventavis
Notes: 2006 figureis an estimatebased onnine-month2006 sales ofCoTherix, which
was acquired byActelion in March2007.
Bayer acquiredSchering AG June23, 2006.
65+
Actelion 65
CoTherix NA
Bayer NA
65+(estimate)
CoTherix 65(estimate)
Bayer NA
24+
CoTherix 24
Schering NA
Actelion and Bayer Pulmonary arterialhypertension
Sept. 22, 2003(EU approval)
479 Canasa 65 53 29 Axcan Pharma Gastrointestinal disorders Jan. 5, 2001
481 Firstcin 64 69 75 TakedaPharmaceutical
Bacterial infections August 1995(Japan launch)
481 Xifaxan 64 52 30 Salix Pharmaceuticals Travelers diarrhea May 25, 2004
481 Cefspan 64 57 60 Astellas Pharma Bacterial infections NA
481 Daytrana 64 25 0 Shire PharmaceuticalsGroup
Attention deficithyperactivity disorder
June 29, 2006(U.S. launch)
-
8/9/2019 Top 500 Medicines Pharma
27/69
27
TOP 500 PRESCRIPTION MEDICINES BY SALES
Rank2007 Medicine
2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions) 2007 company
Primary disease/medical use
First approval date(or launch date)
481 Femhrt 64 59 61 Warner Chilcott Menopausal symptoms Oct. 15, 1999(U.S. approval)
486 Targocid 63 64 70 Astellas Pharma Bacterial infections July 1998
486 Toledomin 63 60 62 Asahi Kasei Depression NA
486 Aptivus 63 73 NA Boehringer Ingelheim HIV infection June 22, 2005
489 Pentcillin 62 61 66 TaishoPharmaceutical
Bacterial infections NA
489 Bredinin 62 60 61 Asahi Kasei Kidney transplantation NA
489 Topotecin 62 54 48 Daiichi Sankyo Colorectal cancer NA
489 Omeprazon 62 59 70 Mitsubishi TanabePharma
Ulcers April 1991 (launch)
489 Novastan 62 54 38 Mitsubishi TanabePharma
Peripheral arterialocclusive disease
NA
494 Nauzelin 60 65 66 Kyowa Hakko Kogyo Gastrointestinal disorders NA
494 Sumiferon 60 64 60 Dainippon Sumitomo Hepatitis B and C 1987
494 Theo-Dur 60 77 127 Mitsubishi TanabePharma
Asthma April 1984 (launch)
497 Bicilin 59 43 54 King Pharmaceuticals Bacter ial infect ions May 19, 1957
497 Cabaser 59 99 103 Kissei Pharmaceutical Parkinsons disease September 1999
497 Antara 59 17 0 OscientPharmaceuticals
Hypercholesterolemia andhypertriglyceridemia
Nov. 30, 2004(U.S. approval)
500 Gastrom 58 61 64 Mitsubishi TanabePharma
Ulcers December 1993(launch)
500 Neuart 58 59 62 Mitsubishi TanabePharma
Disseminated intravascularcoagulation
June 1987 (launch)
NOTES/LEGEND:*First approval date or launch date = anywhere worldwide; in some instances, the first approval or launch date and region of occurrence are provided.*NA = not applicable.*+ = sales are assumed to be higher than the represented total.*This chart presents 500 medicines in sales order as reported by the companies. Certain products are represented by more than one company due to joint-marketing orjoint-promotion accords. The combined product sales from such company alliances are presented in this chart at the top of each medicine sales entry, followed by thebreakdown in company-reported sales.*Some product entries have their (chemical) listed depending on where and under which name the drug is marketed, or how the company reports the drugs sales.*All foreign product sales are reported in U.S. dollars using Federal Reserve or company-provided exchange rates.*Estimate = sales were not provided by company or found by Med Ad Newseditors, who made an estimate based on previous-year figures and/or other information
provided. This report does exclude certain products that probably would have been ranked in the top 500 list for 2007, but were omitted since no 2007 information couldbe found to make an estimate. In most of these instances, there are products with declining annual sales figures due to patent expirations.*All Japanese-company 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006), exceptfor Chugai Pharmaceutical and Kirin Brewery, which report annual sales on a Dec. 31 calendar-year basis.*Forest Laboratories 2007 product sales are for the fiscal year ended March 31, 2008 (2006 = year ended March 31, 2007; 2005 = year ended March 31, 2006).*Barr Pharmaceuticals for 2007 reported on a Dec. 31 calendar-year basis; previously, the company provided figures for years ended June 30).*Axcan Pharma 2007 figures are for the fiscal year ended Sept. 30, 2007 (2006 = year ended Sept. 30, 2006; 2005 = year ended Sept. 30, 2005).
-
8/9/2019 Top 500 Medicines Pharma
28/69
TOP 500PRESCRIPTION
MEDICINES
BY COMPANY
-
8/9/2019 Top 500 Medicines Pharma
29/69
29
TOP 500 PRESCRIPTION MEDICINES BY COMPANY
Company Medicine2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions)
Primary disease/medical use
First approval date(or launch date)
Abbott Laboratories
Note: Abbott acquired KosPharmaceuticals (along withNiaspan and certain rights toCardizem and Teveten) Dec.13, 2006.
Humira 3,064 2,044 1,400 Rheumatoid arthritis Dec. 31, 2002
Depakote 1,575 1,308 1,096 Seizures March 10, 1983
Kaletra 1,325 1,135 1,005 HIV infection March 9, 2001
TriCor 1,218 1,048 927 Cholesterol Feb. 9, 1998
Ultane/Sevorane 759 799 874 Anesthesia June 7, 1995/1994
Biaxin 724 816 1,065 Bacterial infections Oct. 31, 1991
Niaspan 658 0 0 Cholesterol July 28, 1997
Synthroid 533 534 554 Hypothyroidism 1955
Omnicef 235 637 495 Bacterial infections Dec. 4, 1997
Lansoprazole 200 173 154 Gastrointestinal disorders NA
Cardizem LA 129(estimate)
NA 0 Hypertension Feb. 6, 2003
Teveten franchise 27(estimate)
NA 0 Hypertension Dec. 22, 1997(U.S. approval)
Leuprolide NA 230 219 Prostate cancer NA
Synagis
Note: Abbott completedthe U.S. joint-promotiondeal of Synagiswith MedImmune inDecember 2006)
0 373(U.S. jointpromotionrevenue)
231(U.S. jointpromotionrevenue)
Respiratory syncytial virus June 19, 1998(U.S. approval)
Mobic 0 0 1,232 Osteoarthritis andrheumatoid arthritis
Feb. 27, 1996
Abraxis Abraxane 325 175 134 Breast cancer February 2005(U.S. launch)
Diprivan
Note: Abraxis acquiredU.S. rights to Diprivanfrom AstraZeneca inJune 2006.
NA NA 0 Anesthesia Oct. 2, 1989
Actelion Tracleer 983 749 528 Pulmonary arterialhypertension
Nov. 20, 2001
Ventavis
Note: CoTherix and U.S.rights to Ventavis wereacquired by Actelion inMarch 2007.
65 0 0 Pulmonary arterial
hypertension
Sept. 22, 2003
(EU approval)
Akzo Nobel
Note: Akzo Nobel 2007product sales are estimatesfrom Jan. 1, 2007, thru Nov.18, 2007; Schering-Ploughacquired Akzo NobelsOrganon BioSciences as ofNov. 19, 2007.
Follistim/Puregon 513(estimate)
527 487 Infertility Sept. 29, 1997/May 3, 1996
NuvaRing 342(estimate)
292 174 Contraception June 12, 2001
Remeron 271(estimate)
347 388 Depression June 15, 2000
Livial 177(estimate)
207 211 Menopausal symptoms March 1997
Alexion Pharmaceuticals Soliris 66 0 0 Paroxysmal nocturnalhemoglobinuria
April 2007 (U.S. launch)
Allergan Botox 1,212 982 831 Cervical dystonia Dec. 29, 1989
Lumigan franchise 392 328 268 Intraocular pressure March 16, 2001
Restasis 345 270 191 Dry eye Dec. 23, 2002
Alphagan P, Alphagan,Combigan
341 296 277 Intraocular pressure March 16, 2001, Sept. 6,1996, fourth-quarter 2003
Tazorac, Zorac, Avage 80 91 87 Acne, facial wrinkles June 13, 1997, Dec. 12,1996, Sept. 30, 2002
Alpharma Kadian 168 138 102 Pain July 3, 1996
Altana Pharma
Note: Nycomed acquiredAltana Pharma along withPantoprazole productsDec. 29, 2006.
Pantoprazole(including Pantozol)
0 2,126 1,866 Gastrointestinal disorders Pantozol: 1994
-
8/9/2019 Top 500 Medicines Pharma
30/69
30
TOP 500 PRESCRIPTION MEDICINES BY COMPANY
Company Medicine2007 sales($ in millions)
2006 sales($ in millions)
2005 sales($ in millions)
Primary disease/medical use
First approval date(or launch date)
Amgen Aranesp 3,614 4,121 3,273 Anemia June 11, 2001
Enbrel 3,230 2,879 2,573 Rheumatoid arthritis Nov. 2, 1998
Neulasta 3,000 2,710 2,288 Neutropenia Jan. 31, 2002
Epogen 2,489 2,511 2,455 Anemia June 1, 1989
Neupogen 1,277 1,213 1,216 Neutropenia Feb. 20, 1991
Sensipar 463 321 157 Hypercalcemia March 8, 2004
Vectibix 170 39 0 Colorectal cancer Sept. 27, 2006
Amylin Pharmaceuticals Byetta 636 430 75 Type 2 diabetes April 28, 2005
Symlin 66 44 12 Diabetes March 16, 2005
Asahi Kasei Elcitonin 139 138 152 Osteoporosis NA
Flivas 94 93 91 Benign prostatic hyperplasia NA
Toledomin 63 60 62 Depression NA
Bredinin 62 60 61 Kidney transplantation NA
Astellas